Home LiteratureArticle Details
PMID: 17409164 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.

Journal of virology ·Vol. 81 ·No. 12 ·2007-06-00 ·Pages 6187-96

Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SS, Williamson C, Morris L, CAPRISA 002 Study Team

Abstract

The study of the evolution and specificities of neutralizing antibodies during the course of human immunodeficiency virus type 1 (HIV-1) infection may be important in the discovery of possible targets for vaccine design. In this study, we assessed the autologous and heterologous neutralization responses of 14 HIV-1 subtype C-infected individuals, using envelope clones obtained within the first 2 months postinfection. Our data show that potent but relatively strain-specific neutralizing antibodies develop within 3 to 12 months of HIV-1 infection. The magnitude of this response was associated with shorter V1-to-V5 envelope lengths and fewer glycosylation sites, particularly in the V1-V2 region. Anti-MPER antibodies were detected in 4 of 14 individuals within a year of infection, while antibodies to CD4-induced (CD4i) epitopes developed to high titers in 12 participants, in most cases before the development of autologous neutralizing antibodies. However, neither anti-MPER nor anti-CD4i antibody specificity conferred neutralization breadth. These data provide insights into the kinetics, potency, breadth, and epitope specificity of neutralizing antibody responses in acute HIV-1 subtype C infection.

MeSH Terms
Acute Disease Amino Acid Sequence Antibody Formation CD4-Positive T-Lymphocytes/immunology Cloning, Molecular Epitopes/chemistry Female Glycosylation HIV Infections/immunology,virology HIV-1/metabolism HIV-2/metabolism Humans Molecular Sequence Data Neutralization Tests Sequence Homology, Amino Acid
Chemicals
Epitopes
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Gray E S
AIDS Virus Research Unit, National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa.
Moore P L
Choge I A
Decker J M
Bibollet-Ruche F
Li H
Leseka N
Treurnicht F
Mlisana K
Shaw G M
Karim S S Abdool
Williamson C
Morris L
CAPRISA 002 Study Team
References (22)
22 references, click to expand
  1. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
    Science. 2005 Jun 24;308(5730):1906-8 PMID: 15860590
  2. Antigenic conservation and immunogenicity of the HIV coreceptor binding site.
    J Exp Med. 2005 May 2;201(9):1407-19 PMID: 15867093
  3. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    J Virol. 2006 Mar;80(6):3030-41 PMID: 16501112
  4. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.
    J Virol. 2006 May;80(10):4698-704 PMID: 16641263
  5. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.
    J Virol. 2006 Jun;80(11):5211-8 PMID: 16699001
  6. Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes.
    J Virol Methods. 2006 Sep;136(1-2):118-25 PMID: 16701907
  7. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.
    J Virol. 2006 Dec;80(23):11776-90 PMID: 16971434
  8. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.
    PLoS Med. 2006 Jul;3(7):e255 PMID: 16834457
  9. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.
    Structure. 2000 Dec 15;8(12):1329-39 PMID: 11188697
  10. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8 PMID: 11997472
  11. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.
    AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1207-17 PMID: 12487827
  12. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  13. Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9 PMID: 12644702
  14. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains.
    Virology. 2003 Oct 10;315(1):124-34 PMID: 14592765
  15. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Virology. 2004 Mar 30;321(1):8-22 PMID: 15033560
  16. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
    J Virol. 1994 Jul;68(7):4650-5 PMID: 8207839
  17. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.
    J Virol. 1996 Mar;70(3):1651-67 PMID: 8627686
  18. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  19. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.
    J Virol. 1998 Oct;72(10):7840-5 PMID: 9733820
  20. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication.
    AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1129-39 PMID: 9737584
  21. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Science. 1999 Feb 5;283(5403):857-60 PMID: 9933172
  22. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.
    J Virol. 2005 Jul;79(14):9069-80 PMID: 15994801
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.00239-07
Published
2007-06-00
Epub
2007-00-04
Pages
6187-96
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC1900112
Subset
IM
Grants
NIAID NIH HHS · U19 AI051794 · United States
NIAID NIH HHS · U19 AI51794 · United States
Databases
GENBANK
EF203957, EF203958, EF203959, EF203960, EF203961, EF203962, EF203963, EF203964, EF203965, EF203966, EF203967, EF203968, EF203969, EF203970, EF203971, EF203972, EF203973, EF203974, EF203975, EF203976, EF203977, EF203978, EF203979, EF203980, EF203981, EF203982, EF203983, EF203984, EF203985, EF203986, EF203987, EF203988, EF203989
External Links
PubMed source DOI: 10.1128/JVI.00239-07 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2